^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Ovarian Serous Adenocarcinoma
    Drug:prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

    Excerpt:
    ...A documented deleterious germline breast cancer 1 and breast cancer 2 mutation (gBRCA1/2m) obtained in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, including but...
    Trial ID:
    NCT02203513
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Sci Transl Med
    Title:

    BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

    Published date:
    06/21/2023
    Excerpt:
    The aim of this study was to investigate the clinical activity of CHK1i prexasertib in PARPi-resistant BRCA-mutant HGSC and to identify potential biomarkers for CHK1i response….IC50 values for prexasertib monotherapy ranged from 1.2 to 30.6 nM in PARPi-sensitive and -resistant BRCA-mutant HGSC cells...
    DOI:
    10.1126/scitranslmed.add7872